Claude Hariton

PhD, DSc

Vice President and Chief Scientific Officer

• Global Head of Research and Development at Advanced Accelerator Applications (AAA). He led product developments from AAA’s spin-off from European Organization for Nuclear Research (CERN) to listing to NASDAQ and acquisition by Novartis in 2017 for US$4.2B
• Senior management functions with biotechnology and pharmaceutical companies in Switzerland, Canada, Australia, Germany, Spain, France and the United Kingdom
• VP Regulatory Affairs and Drug Safety (Mayne Pharma)
• VP Clinical and Regulatory Affairs and Chief Medical Officer (Aeterna-Zentaris)
• VP Scientific Affairs (Fresenius)
• Global Head of Research and Development (ISDIN)
• Approval of 29 drugs and treatments with the FDA and major regulatory authorities (EMA, TGA, HPFB) including Somakit, NetSpot and Lutathera in oncology, Visudyne, Rescula in ophthalmology and Inovelon/Banzel, Zomaril/Fanapt in neurology
• Led product development from R&D to IPO (AAA) and investment divestitures (Mayne Pharma, Fresenius)
• PhD in Neurosciences from University of Sciences, and DSc in Pharmacology from University of Medicine, Marseille, France